The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics
Narasimhan’s appointment underscores the growing importance of AI in transforming drug discovery
The grant backed by Novartis to strengthen academia-industry collaboration across all seven NIPERs
Each program will rely on partnerships between Novartis teams and local networks—including health authorities, community organizations and private sector groups
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
Subscribe To Our Newsletter & Stay Updated
